ERBB2 and gastric cancer: Preclinical studies revealed an antitumoral effect in HER-2-overexpressing or HER-2-mutant breast, lung and gastric cancer lines [83], and demonstrated that poziotinib upregulates HER-2 expression in the cell membrane and potentiates the antitumoral effect of other anti-HER-2 therapies, such as T-DM1 [84].